MDT

89.97

+2.2%↑

MDT

89.97

+2.2%↑

MDT

89.97

+2.2%↑

MDT

89.97

+2.2%↑

MDT

89.97

+2.2%↑

Search

Maravai LifeSciences Holdings Inc (Class A)

Cerrado

4.13 3.77

Resumen

Variación precio

24h

Actual

Mínimo

3.93

Máximo

4.29

Métricas clave

By Trading Economics

Ingresos

-91M

-99M

Ventas

-8.2M

65M

BPA

-0.02

Margen de beneficio

-151.899

Empleados

580

EBITDA

-158M

-148M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+146.84 upside

Dividendos

By Dow Jones

Próximas Ganancias

25 feb 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

1B

Apertura anterior

0.36

Cierre anterior

4.13

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

Maravai LifeSciences Holdings Inc (Class A) Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

21 feb 2025, 23:22 UTC

Principales Noticias

DOGE Aide's IRS Access Won't Include Personal Information -- Update

21 feb 2025, 23:20 UTC

Ganancias

These Stocks Moved the Most Today: UnitedHealth, Alibaba, Rivian, Celsius, Booking, Block, Akamai, Hims & Hers, and More -- Barrons.com

21 feb 2025, 22:34 UTC

Charlas de Mercado

L'Oréal Cuts Exposure to Chinese Market, Grows Emerging Markets -- Market Talk

21 feb 2025, 22:12 UTC

Principales Noticias

DOJ Investigates Medicare Billing Practices at UnitedHealth -- 2nd Update

21 feb 2025, 21:54 UTC

Principales Noticias

Why Is Warren Buffett Hoarding So Much Cash? -- 2nd Update

21 feb 2025, 21:51 UTC

Ganancias

Tesla Stock Falls. Recalls and Rivian Are in the News. -- Barrons.com

21 feb 2025, 21:50 UTC

Charlas de Mercado
Ganancias

Financial Services Roundup: Market Talk

21 feb 2025, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

21 feb 2025, 21:50 UTC

Principales Noticias

DOGE Aide's IRS Access Won't Include Personal Information -- WSJ

21 feb 2025, 21:48 UTC

Charlas de Mercado
Ganancias

L'Oréal Tops Estée Lauder in Luxury U.S. Market, CEO Says -- Market Talk

21 feb 2025, 21:35 UTC

Charlas de Mercado

Bulk of U.S. Imports From Canada Used to Make U.S. Goods -- Market Talk

21 feb 2025, 21:28 UTC

Principales Noticias

Why Is Warren Buffett Hoarding So Much Cash? -- Update

21 feb 2025, 21:24 UTC

Principales Noticias

Major U.S. Stock Indexes Give Up Gains From the Week -- WSJ

21 feb 2025, 21:19 UTC

Charlas de Mercado

Mexico's Inflation Seen Up in Early February -- Market Talk

21 feb 2025, 20:15 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

21 feb 2025, 20:15 UTC

Charlas de Mercado

JPMorgan Chase Branch Expansion Portends Deposit Growth -- Market Talk

21 feb 2025, 20:05 UTC

Charlas de Mercado

Oil Futures Retreat Into the Weekend Again -- Market Talk

21 feb 2025, 19:58 UTC

Charlas de Mercado

U.S. Natural Gas Futures Post Third Straight Weekly Gain -- Market Talk

21 feb 2025, 19:29 UTC

Charlas de Mercado

Gold Slides After Finding Record High -- Market Talk

21 feb 2025, 19:26 UTC

Principales Noticias

Major U.S. Stock Indexes Slip; UnitedHealth Pulls Down DJIA -- WSJ

21 feb 2025, 19:05 UTC

Charlas de Mercado

Business Conditions Seen as Favoring Corporate Credit -- Market Talk

21 feb 2025, 19:02 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

21 feb 2025, 19:02 UTC

Charlas de Mercado

Corporate Credit Expected to Be Hit Unevenly by Trade Wars -- Market Talk

21 feb 2025, 19:00 UTC

Charlas de Mercado

Long-Term Treasury Yields Expected to Rise -- Market Talk

21 feb 2025, 18:59 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

21 feb 2025, 18:59 UTC

Charlas de Mercado

Policy Haze Makes Longer-Term Treasurys Riskier -- Market Talk

21 feb 2025, 18:58 UTC

Adquisiciones, fusiones, absorciones

Payfare Announces Shareholder Approval of Its Acquisition by Fiserv

21 feb 2025, 18:56 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Celsius Stock Is Soaring. Earnings and Deal News Are Fueling a Big Rally. -- Barrons.com

21 feb 2025, 18:49 UTC

Charlas de Mercado

BOC's Macklem Opens Door to Cuts In Event of Hefty Trump Tariffs -- Market Talk

21 feb 2025, 18:32 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises By Seven to 488 -- Market Talk

Comparación entre iguales

Cambio de precio

Maravai LifeSciences Holdings Inc (Class A) Esperado

Precio Objetivo

By TipRanks

146.84% repunte

Estimación a 12 meses

Media 9.75 USD  146.84%

Máximo 11 USD

Mínimo 8.5 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Maravai LifeSciences Holdings Inc (Class A) Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

5 ratings

3

Comprar

1

Mantener

1

Vender

Puntuación técnica

By Trading Central

N/A / 4.1Soporte y Resistencia

Corto Plazo

Bearish Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.